

## **ATTACHMENT G**

(Copy of Authorization from Q-MED Scandinavia to Q-MED AB  
to Rely Upon Activities of Q-MED Scandinavia Before the FDA  
in Making Its Applications for  
Extension and Extension of Patent Term)

February 10, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner of Food and Drugs  
U.S. Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

**Re: Application for Patent Term Extension  
of U.S. Patent No. 5,827,937**

Gentlemen:

Q-Med Scandinavia, Inc., a subsidiary of Q-Med AB, was the applicant for and currently the holder of the investigational device exemption No. G990258 and premarket approval for Restylane® Injectable Gel No. P020023.


I understand that Q-Med AB is the assignee of the entire right, title and interest of U.S. Patent No. 5,827,937.

Q-Med Scandinavia, Inc. hereby authorizes Q-Med AB to rely upon the activities of Q-Med Scandinavia, Inc. before the U.S. Food and Drug Administration during the regulatory review period in making its application for extension of patent term, and grants the Commissioner for Patents and the Secretary for Health and Human Services and/or Commissioner of Food and Drugs the right to refer to the above P020023 in determining the eligibility of Q-Med AB for such extension.

Sincerely,



Carina Bolin  
Director,  
Q-Med Scandinavia Inc.



Bengt Ågerup  
Director,  
Q-Med Scandinavia Inc.